Envestnet Asset Management
CRDL

Envestnet Asset Management’s Cardiol Therapeutics CRDL Stock Holding History

Envestnet Asset Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,629
Closed -$52.5K – 4502
2025
Q3 		$52.5K Sell
48,629
-133,053
-73% -$161K ﹤0.01% 4473
2025
Q2 		$247K Sell
181,682
-147,467
-45% -$172K ﹤0.01% 4132
2025
Q1 		$315K Buy
329,149
+19,465
+6% +$23.9K ﹤0.01% 3897
2024
Q4 		$398K Buy
+309,684
New +$522K ﹤0.01% 3714
2024
Q3 		– Sell
-26,167
Closed -$52.5K – 4239
2024
Q2 		$52.5K Buy
26,167
+787
+3% +$1.67K ﹤0.01% 4101
2024
Q1 		$45.7K Buy
+25,380
New +$34.2K ﹤0.01% 4113

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Envestnet Asset Management's CRDL Position: Q4 2025 in Review

Envestnet Asset Management sold out of Cardiol Therapeutics (CRDL) in Q4 2025, closing a stake of 48,629 shares — an estimated $52.5K sold.

Envestnet Asset Management first reported a position in CRDL in Q1 2024 and held it in 6 quarters. The position peaked at $398K in Q4 2024. 41 funds tracked by Wall St. Rank hold CRDL as of Q4 2025.

  • Envestnet Asset Management reported no remaining Cardiol Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 48,629 Cardiol Therapeutics shares in Q4 2025, an estimated $52.5K.
  • Envestnet Asset Management first reported a position in Cardiol Therapeutics in Q1 2024 and held it in 6 quarters.
  • Envestnet Asset Management's Cardiol Therapeutics position peaked at $398K in Q4 2024.
  • 41 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q4 2025.

Based on Envestnet Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.